MerLion Pharmaceuticals announces collaborative research agreement with the National Cancer Institute
HIF-1(alpha) over-expression in biopsies of brain, breast, cervical, esophageal, oropharyngeal and ovarian cancers is correlated with resistance to chemotherapy, radiotherapy and mortality. In addition, over-expression is associated with increased vascularity and tumor progression and has been observed in more than 70% of human cancers and their metastases including bladder, breast, colon, glial, hepatocellular, ovarian, pancreatic, prostate, lung, renal and head and neck cancers
Under this Cooperative Research and Development Agreement (CRADA), MerLion will perform initial screening and identification of candidate molecules. Both parties may then further investigate and develop these drug candidates for use in potential clinical investigations.
The NCI-STB has a long and well-documented track record in lead discovery from natural products as well as small molecule chemical libraries. More recently the STB has developed a number of cell-based high throughput assays used to identify small molecule inhibitors of molecular targets relevant to cancer growth and angiogenesis.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.